Home › Stocks › Pharma & healthcare stocks › Fortis Healthcare
Pharma & healthcare stocks Valuation research

Fortis Healthcare fair value — the IHH turnaround

Fortis fell into crisis under its founders, was taken over by Malaysia's IHH Healthcare in 2018, and has since returned to steady profits.

FairStocks Research
Updated 16 Nov 2026 · 4 min read
| NSE: FORTIS ₹764
On this page ▾
  1. The business
  2. What the market assumes
  3. The ten-year record
  4. How it is valued
  5. What decides the value
  6. What could go wrong
  7. The full valuation
  8. Questions
Fortis Healthcare (FORTIS) fair value — is it overvalued? Price ₹764, P/E 55.6, P/B 5.83, ROE —. Based on 10 years of reported financials. FairStocks.
Fortis Healthcare at a glance. Share price, P/E, P/B and the ten-year revenue trend, from filed accounts. Updated 16 Nov 2026.
In 30 seconds

The market expects Fortis Healthcare to carry on much as it has.

At today’s share price, buyers are assuming Fortis Healthcare grows about 14% a year, forever. Over the last ten years it actually grew about 13% a year. The two are close, so the share price does not need the business to improve or to stumble. It needs it to keep doing roughly what it already does.

  • How it is valued: Discounted cash flow.
  • What the price assumes: 14% growth, against 13% the model takes from its own record.
  • Ten-year record: Between FY2018 and FY2026, Fortis Healthcare's revenue went from ₹4,561 crore to ₹9,128 crore — it compounded at about 9% a year over 8 years.
  • Biggest swing factor: Occupancy and pricing. Main risk: Litigation.
Price
₹764
Market cap
₹0.58L Cr
P/E
55.6
P/B
5.83
See Fortis' fair value and the full DCFEvery step of the Fortis Healthcare working, the scenarios and the report Free during launch →

01Hospitals and diagnostics

Fortis Healthcare runs a network of hospitals across India, including Fortis Memorial Research Institute in Gurugram, and owns most of Agilus Diagnostics, formerly SRL.

Its founders, Malvinder and Shivinder Singh, lost control amid financial troubles, and Malaysia's IHH Healthcare became the controlling shareholder in 2018.

02What the market is assuming

Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Fortis Healthcare, next to what the model assumes from the company's own record.

Market expects
14%
growth priced into today's price
Model assumes
13%
growth the model assumes

The further apart these two numbers are, the bigger the bet a buyer at today's price is making.

03Fortis Healthcare's record, in plain numbers

Between FY2018 and FY2026, Fortis Healthcare's revenue went from ₹4,561 crore to ₹9,128 crore — it compounded at about 9% a year over 8 years. It reported a net loss in FY2018, FY2019 and FY2021, and closed the period with net profit of ₹1,064 crore. In FY2026 it kept 11.7% of revenue as net profit — against a low of -20.5% in FY2018 and a high of 13.8% in FY2022. The latest year added 17.3% to revenue, well ahead of its own long-run pace.

Reading the record. The losses in FY2018–FY2019 came during the crisis under its former promoters; profits have recovered under IHH.
Revenue₹0.05L → ₹0.09L Cr
181920212223242526
Earnings per share₹-19.5 → ₹13.8
181920212223242526
Return on equity-4.8% → 26.1%
19202122232526

Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.

Revenue and net profit by year (₹ crore)
YearRevenueNet profitMargin
FY20184,561-934-20.5%
FY20194,469-224-5.0%
FY20204,632912.0%
FY20214,030-56-1.4%
FY20225,71879013.8%
FY20236,29863310.1%
FY20246,8936459.4%
FY20257,78380910.4%
FY20269,1281,06411.7%

04How Fortis Healthcare gets valued — and why

Discounted cash flow

This business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.

05What decides Fortis Healthcare's value

Occupancy and pricing

Fuller beds and complex care lift margins.

New beds

Expansion adds capacity.

Diagnostics

Agilus adds a second business.

Legal overhangs

Old disputes from the founder era.

06What could go wrong

  • Litigation. Legal cases linked to the old promoters.
  • Price caps. Regulation could limit pricing.
  • Competition. Apollo, Max and others are expanding.

07What the full Fortis valuation shows

Model value per share
₹0,000
Upside
+00%
Call
XXXX

Sign in free to see the complete Fortis Healthcare valuation

  • ✓Fair value per share — from a ten-year discounted cash flow, every step shown
  • ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Fortis' value move
  • ✓Bull, base and bear cases — and exactly which assumptions move between them
  • ✓Peer comparison — against Apollo Hospitals and Max Healthcare
  • ✓Downloadable report — the full write-up, yours to keep
See Fortis' fair value and the full DCF — free
Free during launch · unlimited valuations · no card required

08Questions people ask about Fortis Healthcare

Who owns Fortis Healthcare?

Malaysia's IHH Healthcare is the controlling shareholder.

What is Agilus Diagnostics?

Fortis' diagnostics business, formerly SRL.

Why did Fortis make losses?

Financial troubles under its former promoters before IHH took over.

Is Fortis Healthcare overvalued?

At ₹764 the market is pricing in roughly 14% sustained growth, against the ~13% its own record supports. That is close to what it has delivered, so the price is broadly consistent with the company simply continuing as it has.

What is the intrinsic value of Fortis Healthcare?

It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.

About this research

Written by the FairStocks research team from Fortis Healthcare's filed accounts and last reviewed 5 Oct 2026; the figures refresh as new results are filed. Every valuation uses the method that fits the business and shows its assumptions — see a fully worked example or the valuation guides. Educational research, not investment advice.

See Fortis' fair value and the full DCFUnlock free